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The human proto-oncogene bmi-1 is a member of the mammalian
Polycomb Group (Pc-G) family genes which are required during
development to maintain stable repression of specific target
sequences, such as homeo-box-cluster genes (Paro, 1995; Gould,
1997; van Lohuizen, 1998). bmi-1 was identified as one of the first
Pc-G genes (Brunk et al, 1991; van Lohuizen et al, 1991b) by
retroviral insertional mutagenesis when Em-myc transgenic mice
were infected with Moloney murine leukaemia virus (bmi-1: 
B-cell specific Moloney murine leukaemia virus insertion site 1)
leading to a marked decrease in the latency period preceeding the
development of pre-B-cell lymphomas in mice from approxi-
mately 150 to 50 days. Analysis of these tumours showed a variety
of retroviral insertion sites with frequent integration near bmi-1,
resulting in its overexpression (Haupt et al, 1991; van Lohuizen 
et al, 1991a). In vitro data has shown that bmi-1 overexpression in
normal/primary human fibroblasts yields a proliferative advantage
and delays the Hayflick limit in TIG3 cells (Jacobs et al, 1999;
Voncken et al, 1999). Conversely, bmi-1–/–mice suffer from neuro-
logical and severe proliferative defects in lymphoid cells (van 
der Lugt et al, 1994; Alkema et al, 1997b). Mouse embryonic
fibroblasts deficient for bmi-1 expression show impaired progres-
sion in the S phase of the cell cycle and premature senescence. 
It has been recently reported (Jacobs et al, 1999) that the
INK4a-ARF tumour suppressor locus is a critical downstream
target of bmi-1. Specifically, bmi-1 acts as a negative regulator of
the INK4a-ARF locus, which encodes the two tumour suppressors
p16INK4a and p14ARF (=human p19ARF). p16INK4a inhibits
cell cycle progression by inhibiting cyclin D1-dependent kinases
and thereby prevents the phosphorylation of the tumour suppressor
Rb (Whyte, 1995) whereas p14ARF prevents the degradation and
inactivation of the tumour suppressor p53 by binding to mdm-2
(Pomerantz et al, 1998; Zhang et al, 1998; Weber et al, 1999).
Overexpression of bmi-1 allows fibroblast immortalization, down-
regulates expression of p16INK4a and p14ARF and, in combina-
tion with H-ras, leads to neoplastic transformation. Removal of the
INK4a-ARF locus dramatically reduces the lymphoid and neuro-
logical defects seen in bmi-1–/–mice, indicating that the INK4a-
ARF locus is a critical in vivo target for bmi-1. Such a hypothesis
is further supported by data correlating low levels of bmi-1 with
markedly raised expression of p16INK4a and p14ARF in lympho-
cytes (Jacobs et al, 1999). 
To test whether this regulatory mechanisms obtained in model
systems might have relevance in primary human epithelial
tumours, we initiated this study to assess the bmi-1 expression in a
series of non-small cell lung cancer well documented for
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p16INK4a, p14ARF, cyclin D1 and pRb expression. We show that
bmi-1 is differentially expressed and that protein levels in the
tumour cells are associated with the INK4a-ARF locus 
expression. 
PATIENTS, MATERIAL AND METHODS 
Patients’ characteristics 
Tumour samples were obtained from 48 patients (45 men, 3
women, median age of 65 years (45–79)) who had undergone
resection at our hospital. They had received no therapy prior to
surgery. 29 patients were in stage I, 7 in stage II and 12 in stage III:
32 were squamous cell carcinomas, 9 adenocarcinomas, 4 undif-
ferentiated NSCLC, 2 large cell carcinomas and 1 carcinoid
tumour. 18 of 48 patients are alive with a median follow-up of 20
months (range 1–64). 
Cell lines 
All cell lines were cultured in a humidified CO2 incubator at 37˚C
in RPMI 1640 or DMEM (Sigma, St. Louis, MO) supple-
mented with 10% fetal calf serum, 100 mgm l –1 streptomycin and
100 U ml–1 penicillin. 
Paraffin embedding of cell lines 
Cells were fixed in 4% formaldehyde and embedded in 4%
agarose. The agarose button was processed to paraffin wax and
immunostained as tissue sections. 
Immunohistochemistry 
For bmi-1, 4 mm formalin-fixed, paraffin-embedded sections were
dewaxed, rehydrated, and boiled (microwave) in EDTA buffer (pH
8.0). Sections were stained with the monoclonal anti-bmi-1F6
antibody (1: 200; (Alkema et al, 1997a)). As an internal control for
staining intensity we used lymphocytes, which have been shown to
express bmi-1 protein. Staining intensity was assessed as follows:
negative-weakly (– – +), moderately (++) and strongly (+++)
positive. Slides were assessed blinded, without knowledge of the
expression of p16INK4a and p14ARF. 
The staining for p16INK4a and p14ARF was performed as
described previously (Betticher et al, 1996, 1997; Vonlanthen et al,
1998). 
Western blot analysis 
Cells and tumour tissues were lysed in a Nonidet P40 lysis buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% v/v
NP-40 and protease inhibitors (complete™, Roche, Basel,
Switzerland)). 100 mg of total protein was size-fractionated 
by SDS-Page and transferred to nitrocellulose (Schleicher and
Schuell, Riehen, Switzerland). Equal loading was controlled 
by staining the membrane with Ponceau S (Sigma, Buchs,
Switzerland). The membrane was probed with a monoclonal anti-
bmi-1-F6 antibody (Alkema et al, 1997a), 1:1500 in TBS-T
containing 1% dried milk or a polyclonal anti-p19ARF antibody
(RB-045, Neomarkers, 1:200 in TBS-T containing 2% dried milk),
which recognizes also the human homologue p14ARF. Detection
was performed using an enhanced chemiluminescence system
(ECL, Amersham, Zurich, Switzerland) according to the
manufacturer’s recommendations 
Comparative multiplex PCR 
Tumours were screened for amplification of the bmi-1 gene by
comparative multiplex PCR. Test primers (Bmi3f 5¢cagatggcat-
tatgcttgttgtac, Bmi3r 5¢gtaagcaaggctcaacatagct) were located in
the 3¢untranslated region of bmi-1. Control primers (PR1
5¢ggtttgtttctcactcatatagc, PR2 5¢gtaggacctcaaggtgtagc) were
located in genomic sequence flanking the progesterone receptor
gene on chromosome 11q22–23. 50 ml PCR reactions contained
four primers (Bmi3f, 0.5 mg; Bmi3r, 0.5 mg; PR1, 0.125 mg; PR2,
0.125 mg), 1´ Taq reaction buffer (Roche), 250 mM dNTPs
(Roche) and 1.25 units of Taq polymerase. Reactions were cycled
30 times in a PE Applied Biosystems GeneAmp PCR System 9700
machine at 58˚C for 1 min, 74˚C for 1 min and 94˚C for 1 min,
with a final cycle of 58˚C for 1 min, 74˚C for 3 min. Products were
visualized on 2.75% TBE agarose gels. The PCR reaction is
competitive, with an amplification of either gene leading to a
reduction in the PCR product intensity of the other. Reactions were
balanced (by adjusting the initial primer concentration) to give
approximately equal amounts of test and control products from a
DNA target isolated from histologically normal lung tissue. The
ratio of test to control bands derived from the tumour samples was
assessed visually with reference to the control reactions. 
Statistical analyses 
Associations of group membership with tumour characteristics
were made with Fisher’s exact tests for categorical features and the
Mann–Whitney non-parametric test for continuous variables.
Kaplan–Meier survival function estimates were used and simple
comparisons between the two groups were made with the log-rank
test. 
RESULTS AND DISCUSSION 
Bmi-1 expression in human cell lines 
As a first step we studied the expression of bmi-1 in immunohisto-
chemistry (IHC) experiments. Since the antibody has been shown
to be specific in mice (Alkema et al, 1997a), the conditions for
IHC for the bmi-1 monoclonal antibody were initially defined in
human thymic and spleen tissues known to express high levels of
bmi-1 (van Lohuizen et al, 1991a). Subsequently, the antibody was
tested in a series of human cell lines by immunoblotting and IHC.
In particular, 11 human cancer cell lines and 2 normal lung fibro-
blasts cell lines (IMR-90 and Wi-38) were prepared in the same
manner as the tumours and examined for bmi-1 expression. Bmi-1
expression levels assessed by immunoblotting were in agreement
with the IHC results in all cases. 4 cell lines expressed high levels
of bmi-1 protein (leukaemia/lymphoma cells: Karpas 620, KG-1,
Molt-4, and the breast MDA-MB 453 cell line). 5 further cell lines
(K562 (leukaemia), MCF-7 (breast), Sa-OS-2 (bone), A549 and
Calu-1 (lung)) exhibited moderate levels of bmi-1, and finally the
2 normal lung fibroblast cell lines (IMR-90 and Wi-38) as well 
as the HL-60 leukaemia line and Sk-ut-1B (uterus) were 
negative–very weakly positive for bmi-1 protein expression. 
In immunoblotting experiments, the antibody recognized up to 
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representing phosphorylated isoforms of the protein (Alkema et al,
1997a; Voncken et al, 1999). In conclusion, bmi-1 levels tend to be
higher in cancer-derived human cell lines as compared to the 2 normal
lung fibroblast lines. These results are in agreement with published
data (Alkema et al, 1993; Lessard et al, 1998; Voncken et al, 1999). 
Bmi-1 expression in normal lungs and NSCLC 
In normal lungs, stained by IHC, bmi-1 protein was
weakly–moderately expressed in some epithelial cells, lympho-
cytes, glandular cells and in fibroblasts, whereas blood cells, 
endothelial, chondrocytes, muscle cells and adipocytes did not
exhibit any bmi-1 expression. In tumours, malignant cells were
negative–weakly, moderately or strongly positive in 20, 22 and 6
cases respectively (Figure 2 A, B). No association of bmi-1 protein
expression with tumour criteria (proliferation rate, differentiation,
size, histology classification) and patient’s outcome were found
(Figure 3), perhaps due to the low number of tumours examined.
In conclusion, 58% of resectable NSCLC exhibit moderate to high
levels of bmi-1. To our knowledge, this is the first description of an
altered expression pattern of a Pc-G oncoprotein in human solid
tumours. 
In order to corroborate these IHC results in tumours, we
performed immunoblotting analyses in several available tumour
specimens. All tumours positive in IHC experiments exhibited a
strong bmi-1 signal in immunoblots. Thus, it appears that both
techniques, IHC and immunoblotting, can be used with this anti-
body for examining high-level bmi-1 expression in human malig-
nant cells. However, we also observed a bmi-1 signal in
immunoblots of some IHC-negative tumours, in particular if the
lymphocytic infiltration was significant. Since we tested the anti-
body in cell lines (preparation identical as for tumours) and
showed a strong association between immunoblotting and IHC, we
assume that the bmi-1 bands obtained in IHC-negative tumours
originate from the numerous contaminating non-malignant cells,
in particular lymphocytes, expressing moderate levels of bmi-1. 
Associations of bmi-1 with INK4a-ARF locus
expression 
The present tumour series has been previously studied for
p16INK4a (Betticher et al, 1997) and human p19ARF (=p14ARF)
(Vonlanthen et al, 1998) expression. In order to corroborate the
staining results we performed further immunoblotting in a subset
of tumours that showed good correlation between immunoblotting
and IHC (Figure 4). Regarding the recently described function of
bmi-1, namely to regulate the INK4a-ARF locus, we looked for
associations of bmi-1 and p16INK4a/p14ARF expression. In the
present tumour series normal p16INK4a and p14ARF expression
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Figure 1 Immunoblotting of bmi-1 in human cell lines 
Figure 2 Immunohistochemistry of bmi-1: tumour with positive (A) and
negative (B) staining 
Figure 3 Overall survival of patients with resectable NSCLC whose
tumours expressed no–weak or moderate–strong levels of bmi-1 
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was found in 25/48 and 19/48, respectively (Vonlanthen et al,
1998). Some of the tumours exhibited normal p14ARF expression,
whilst p16INKa was downregulated by strong methylation of the
exon 1 alpha. Furthermore, a series of tumours (8/48) were nega-
tive for both p16INK4a and p14ARF expression. No methylation
of exon 1 alpha nor mutations were found in the CDKN2
(p16INK4a) gene. We were also unable to demonstrate homozy-
gous loss at the CDKN2 locus in any case (Betticher et al, 1997).
Interestingly, these 8 tumours have strong–moderate bmi-1
expression. Out of a further 4 tumours, in which both proteins
(p16INK4a and p14ARF) were downregulated and showed strong
methylation of the exon 1 alpha, 3 also had bmi-1 expressed at
high levels. Conversely, low levels of bmi-1 was associated with
normal p16INK4a and p14ARF expression (P = 0.02). These
results support the hypothesis that increased expression of 
bmi-1 in primary human tumour cells leads to downregulation 
of the INK4a-ARF locus thereby impacting on both the
p16INK4a-CDK4-cyclin D1-pRB and the p14ARF-mdm-2-p53
pathways. 
Bmi-1 gene amplification analysis in NSCLC 
In order to investigate the mechanism underlying the overexpres-
sion of bmi-1 in resectable NSCLC, we examined whether the
bmi-1 gene on chromosome 10p13 was amplified. Previously, in 2
blastoid mantle cell lymphomas amplification of the bmi-1 gene
was found by Southern blot analysis (Bea et al, 1999).
Comparative multiplex PCR was used to compare bmi-1 copy
number to that of the progesterone receptor gene localized at
11q22–23. None of the 48 tumours showed an imbalance 
(favouring bmi-1) between test and control PCR products,
suggesting that bmi-1 was not amplified in any of the lesions
(Figure 3). It would therefore appear that an alternative mecha-
nism(s) generates the bmi-1 overexpression. Candidates for such a
mechanism include point mutation of control regions or coding
sequence (leading to a stabilization of the protein), translocational
upregulation, or alterations in transcription factor expression in the
host cells. Further studies will be required to identify the particular
cause of the overexpression of bmi-1 in lung carcinomas. 
In conclusion, our results show that one of the polycomb group
proteins, bmi-1, is differentially expressed in resectable NSCLC.
The finding that this expression variance is associated with the
expression of tumour suppressors encoded by the INK4a-ARF
locus supports existing hypotheses developed in mice models and
further suggests a role in lung cancer pathogenesis for the deregu-
lation of bmi-1. 
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